A 25-year-old San Francisco founder is building a peptide subscription business on the premise that FDA deregulation will keep expanding. No SEC Form D documents who's actually backing it.

A San Francisco startup called Superpower is selling memberships that bundle comprehensive annual lab testing with access to legal peptides — compounds like GLP-1s, sermorelin, and SS-31, marketed for body recomposition, anti-aging, and energy. Business Insider profiled the company in March 2026, calling it a consumer health startup riding a wave of Silicon Valley's peptide obsession.

The founder is Max Marchione, 25, who told Business Insider he noticed "many, many people" in San Francisco getting peptide-pilled in late 2025 and saw a business. Superpower began offering peptide access in January 2026. Marchione's stated strategy is blunt: "When a peptide is legal, we are going to sell it" — a business model that is explicitly predicated on the FDA continuing to loosen restrictions under the RFK Jr.-led HHS agenda. In late February, Kennedy announced the FDA would lift restrictions on 14 peptides.

That's a lot of regulatory exposure for a company with no publicly documented financial backing. A search of SEC EDGAR turns up no Form D filing for an operating company matching Superpower's description — meaning either the company is pre-raise, raised under a legal entity name that doesn't surface under the brand, or is structured to avoid the threshold that triggers Form D disclosure. Marchione has not publicly named investors or disclosed a round size. The Business Insider story doesn't name backers either.

Hacker News engagement with the Business Insider profile: 2 points, 0 comments.

The peptide market is real — GLP-1s alone are a projected $100 billion category by 2030, per market estimates cited by Marchione. But Superpower's pitch is downstream of a specific federal policy posture, and the company's cap table and runway are undisclosed. The next thing to watch: whether a Form D surfaces, and whether the FDA's peptide deregulation holds past the current administration's tenure.